Nana Asiedu , Emmanuel Kiiza Mwesiga , Dickens Akena , Corey Morrison , Joy Louise Gumikiriza-Onoria , Angel Nanteza , Juliet Nakku , Nastassja Koen , Noeline Nakasujja , Wilber Ssembajjwe , Christopher M. Ferraris , Anthony F. Santoro , Dan J. Stein , Reuben N. Robbins
{"title":"Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients","authors":"Nana Asiedu , Emmanuel Kiiza Mwesiga , Dickens Akena , Corey Morrison , Joy Louise Gumikiriza-Onoria , Angel Nanteza , Juliet Nakku , Nastassja Koen , Noeline Nakasujja , Wilber Ssembajjwe , Christopher M. Ferraris , Anthony F. Santoro , Dan J. Stein , Reuben N. Robbins","doi":"10.1016/j.scog.2022.100276","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Neurocognitive impairment (NCI) is commonly exhibited among patients experiencing their first episode of psychosis. However, there are few resources in many low-income countries, such as Uganda, that allow for the administration of extensive neurocognitive test batteries for the detection of NCI. <em>NeuroScreen</em> is a brief tablet-based neurocognitive assessment battery that can be administered by all levels of healthcare staff. We examined the validity of <em>NeuroScreen</em> to assess neurocognition and detect NCI in first-episode psychosis (FEP) patients in Uganda.</p></div><div><h3>Methods</h3><p>We enrolled 112 participants FEP patients and matched controls at Butabika Mental Referral Hospital. Each participant completed <em>NeuroScreen</em> and a traditionally administered neurocognitive battery: the MATRIC Consensus Cognitive Battery (MCCB). We examined correlations between participant performance on <em>NeuroScreen</em> and the MCCB. A ROC curve determined sensitivity and specificity of <em>NeuroScreen</em> to detect NCI as determined by MCCB criterion.</p></div><div><h3>Results</h3><p>There was a large, statistically significant correlation between overall performance on <em>NeuroScreen</em> and the MCCB [<em>r</em>(112) = 0.64, <em>p</em> < .001]. Small to large correlations were found between tests in the MCCB and <em>NeuroScreen</em> batteries. The ROC curve of <em>NeuroScreen</em> performance to detect MCCB-defined NCI had an area under curve of 0.80 and optimal sensitivity and specificity of 83 % and 60 %, respectively.</p></div><div><h3>Conclusion</h3><p>There was a moderate positive correlation between overall performance on both batteries. <em>NeuroScreen</em> shows promise as a valid assessment battery to assess neurocognition and detect NCI in FEP patients in Uganda. Further studies of <em>NeuroScreen</em> in healthy individuals and in a range of mental disorders are recommended.</p></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8e/10/main.PMC9803945.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Schizophrenia Research-Cognition","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2215001322000415","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Neurocognitive impairment (NCI) is commonly exhibited among patients experiencing their first episode of psychosis. However, there are few resources in many low-income countries, such as Uganda, that allow for the administration of extensive neurocognitive test batteries for the detection of NCI. NeuroScreen is a brief tablet-based neurocognitive assessment battery that can be administered by all levels of healthcare staff. We examined the validity of NeuroScreen to assess neurocognition and detect NCI in first-episode psychosis (FEP) patients in Uganda.
Methods
We enrolled 112 participants FEP patients and matched controls at Butabika Mental Referral Hospital. Each participant completed NeuroScreen and a traditionally administered neurocognitive battery: the MATRIC Consensus Cognitive Battery (MCCB). We examined correlations between participant performance on NeuroScreen and the MCCB. A ROC curve determined sensitivity and specificity of NeuroScreen to detect NCI as determined by MCCB criterion.
Results
There was a large, statistically significant correlation between overall performance on NeuroScreen and the MCCB [r(112) = 0.64, p < .001]. Small to large correlations were found between tests in the MCCB and NeuroScreen batteries. The ROC curve of NeuroScreen performance to detect MCCB-defined NCI had an area under curve of 0.80 and optimal sensitivity and specificity of 83 % and 60 %, respectively.
Conclusion
There was a moderate positive correlation between overall performance on both batteries. NeuroScreen shows promise as a valid assessment battery to assess neurocognition and detect NCI in FEP patients in Uganda. Further studies of NeuroScreen in healthy individuals and in a range of mental disorders are recommended.